Modern Medicine News

Physician groups brace for vaccine questions amid Trump presidencyBetween public skepticism on vaccinations and provisions of the American Health Care Act, some representing physicians are voicing concern.
Researchers target potent HIV antibodies in new studyThe newly discovered antibodies can fight nearly every strain of HIV in existence, according to study authors.
What are small practices saying about telemedicine?While leaders in healthcare are pushing for an era of digital care, many providers on the frontlines have remained silent observers.
Study: DAA all-oral combination successful in treating hepatitis CEarly data shows promise in “real-world” effectiveness.
Real-world DAA therapy shows gains in community settingPhysicians have a “good, effective, safe therapy available” for hepatitis C virus genotype 6 patients, says researcher.
Millennial urologists display a political awakeningMillennial urologists appear to have developed strong opinions on health policy as reflected by their recent social media activity, observes urologist Alan L. Kaplan, MD.
Why opticals must exceed, not meet, expectations
Why opticals must exceed, not meet, expectations
Advances in lasers, light sourcesLaser and light source treatments target many of the most common skin conditions that dermatologists encounter. The recent expansion in laser dermatology is both promising and exciting as the treatments available to derms and their patients continue to grow. New technologies are taking laser and light source treatments in new directions of skin structure imaging, epidermal harvesting, tissue rejuvenation, and new types of photodynamic therapies.
Understanding and using biosimilarsBiosimilars have the potential to lower the high costs of biologic treatments for patients suffering from chronic skin diseases. Although biosimilars have received FDA approval derms still have many questions about what they are and when they may be used appropriately. Patent wars and a lack of rules and regulations at the state level add to the confusion about using biosimilars.
Therapies for hidradenitis suppurativaTNF inhibitors adalimumab and infliximab have evidence-based efficacy for the treatment of hidradentitis suppurativa (HS). Anti-interleukin inhibitors ustekinumab and anakinra also being evaluated in small studies for treatment of HS. Antibiotics, hormones, retinoids, steroids and laser therapies directly targeting the lesions round out an effective treatment plan for HS patients.